HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
ID: 348053Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348053

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-191.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for research on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This initiative aims to support innovative studies that explore the relationship between HIV and the development of NCDs, enhance research capacity, and foster collaboration among researchers in LMICs, particularly focusing on conditions such as diabetes, cardiovascular diseases, and mental health disorders. The total budget for each two-year project is capped at $275,000, with applications due by 5 PM local time on December 8, 2023. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-191-Full-Announcement.html
    PAR-23-191.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity aimed at HIV-associated non-communicable diseases (NCDs) research at low- and middle-income country (LMIC) institutions. The initiative focuses on enhancing research capacity and collaboration among researchers addressing the significant burden of NCDs in people living with HIV (PLWH). The R21 exploratory/developmental grant will fund innovative studies in areas including diagnostics, therapeutic interventions, and epidemiological insights, emphasizing the importance of understanding HIV’s role in accelerating NCD development. The program invites diverse research partnerships and encourages studies that explore the impact of HIV on conditions such as diabetes, cardiovascular diseases, and mental health disorders. Applications are due by 5 PM local time of the applicant organization, with the first deadline on December 8, 2023. Funding availability will depend on NIH appropriations and the quality of submissions. The total budget for a two-year project cannot exceed $275,000. This funding aims to stimulate research that translates into prevention strategies and integrated care models in resource-constrained settings, ultimately improving health outcomes for PLWH in LMICs.
    Similar Opportunities
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD," aimed at stimulating research related to HIV/AIDS and communication disorders. This initiative encourages applications that address high-priority research areas defined by the NIH Office of AIDS Research, focusing on the impact of HIV on hearing, balance, taste, smell, voice, speech, and language, with a budget limit of $275,000 for a two-year project period. Eligible applicants include a diverse range of institutions and organizations, and only low-risk clinical trials that do not require FDA oversight will be supported. Interested parties can find more information and application details at the NIH grants website, with deadlines for submissions ranging from May 2025 to January 2028.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK." This funding initiative aims to support innovative pilot research projects that explore the biological, behavioral, and social mechanisms related to HIV pathogenesis, particularly focusing on comorbidities and complications affecting organs and tissues relevant to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The research is expected to enhance understanding of the interplay between HIV and associated health issues, with a funding cap of $275,000 over two years for successful applications. Interested applicants, including higher education institutions and various nonprofit organizations, should note that the application deadlines begin in April 2025, with the final submission date set for January 7, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Multidisciplinary Studies of HIV/AIDS and Aging," aimed at exploring the intersection of HIV and aging. This initiative seeks to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, while also improving strategies for testing, prevention, and treatment of HIV-related health complications. Given the increasing number of older adults living with HIV, this research is crucial for addressing public health challenges and improving healthcare delivery across diverse populations. The funding supports exploratory research under the R21 mechanism, with a maximum budget of $275,000 for two years, and applications are due between May 2025 and January 2027. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-355.html.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at exploring the role of inflammasomes in the context of HIV infection and substance use disorders. This R21 exploratory grant encourages research into the mechanisms of inflammasome activation and their association with neurocognitive disorders in individuals affected by HIV and substance use, with a focus on identifying molecular markers and potential therapeutic innovations. The total funding available is up to $2 million over two years, with applications opening on February 13, 2024, and a submission deadline of March 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.